Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $7.73B
• Dividend Yield: 0.65%
• Average Volume (3M): 2.48M
• Price to Earnings (P/E): 59.9
• Beta (1Y): 0.92
• Revenue Growth: 4.72%
• EPS Growth: -35.33%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.56
• Shares Outstanding: 156,767,290
• 10 Day Avg. Volume: 2,858,799
• 30 Day Avg. Volume: 2,475,289
• PEG Ratio: 9.51
• Price to Book (P/B): 3.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 31.05
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 1.73
• Enterprise Value/Gross Profit: 10.31
• Enterprise Value/Ebitda: 5.70
• 1Y Price Target: $72.40
• Price Target Upside: 46.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

Bio-Techne demonstrates robust financial health with strong profitability and low leverage. However, technical indicators suggest bearish momentum, and high valuation raises concerns. The company navigates well through macroeconomic challenges as highlighted in the earnings call, but ongoing legal and tariff issues present risks.

Positive Factors

Financial Performance

Bio-Techne reported better-than-expected financial results for their 3Q25, including revenues of $316.2 million, an increase of 4.2% year-over-year, and increased adjusted earnings of $0.56 as compared to $0.48 one year ago.

Growth in Innovative Products

Longer-term, demand for Bio-Techne’s innovative products and systems for the cell and gene therapy market should balance out any downturn from decreases in government R&D funding.

Share Repurchase Program

Operating cash flow was positive in the quarter for Bio-Techne at $41.1 million, helping to maintain cash balances at $140.7 million after dividends, CapEx, and share buybacks, and allow the Company’s Board to authorize a new $500 million share repurchase program.

Negative Factors

Academic Funding Challenges

Techne is in the crosshairs of many macro and industry headwinds such as weaker U.S. academic/NIH funding, slower biotech funding, increased China uncertainty, and tariffs.

Reduced Organic Growth Guidance

Updated guidance for fiscal fourth quarter now calls for low-single-digit organic growth, down from high-single-digit growth.

Tariffs Impact

Company management was somewhat cautious in providing forward guidance for 4Q25E, due to uncertainties related to US government spending on R&D programs and the impact of tariffs on China and other international markets.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Bio-Techne makes money through the sale of its diverse portfolio of life science and diagnostic products. The company's revenue model is primarily based on product sales, with key revenue streams coming from its Protein Sciences segment, which includes proteins, antibodies, and immunoassays, and its Diagnostics and Genomics segment, which provides diagnostic reagents and instruments. Bio-Techne also generates income through collaborations and partnerships with academic institutions, pharmaceutical companies, and healthcare organizations. These partnerships often involve co-development agreements, licensing deals, and supply agreements, which contribute to the company's earnings.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne exhibits solid financial health with strong revenue growth and profitability. The balance sheet is stable with low debt levels, and cash flow remains robust. Despite some challenges in net profit margins and increasing debt, the company's overall financial position is strong, supporting continued growth and resilience in the biotechnology sector.

Income Statement

Bio-Techne demonstrates strong revenue growth with a consistent upward trajectory over the years, evidenced by a 3.3% increase in revenue from 2023 to 2024 (TTM). The company maintains robust profitability with a gross profit margin of 65.8% and an EBIT margin of 19.9% for TTM. However, the net profit margin has decreased, reflecting a decline in net income, suggesting potential cost pressures or other operational challenges.

Balance Sheet

The company maintains a healthy balance sheet with a Debt-to-Equity ratio of 0.18 in TTM, indicating low leverage and financial stability. The equity ratio stands at 78.2%, showcasing strong equity backing. However, there is a slight increase in total debt, which could pose a risk if not managed well.

Cash Flow

Operating cash flow remains strong with a 1.93 ratio to net income in TTM, indicating efficient cash generation. Free cash flow shows growth, although at a slower pace compared to previous years. The company efficiently converts its earnings into cash flow, supporting its operational liquidity and investment activities.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.20B	1.16B	1.14B	1.11B	931.03M	738.69M
	Gross Profit
787.02M	769.73M	769.82M	756.50M	632.85M	483.19M
	EBIT
238.38M	206.69M	298.94M	296.59M	149.55M	74.68M
	EBITDA
344.88M	310.37M	460.56M	420.12M	258.47M	373.91M
	Net Income Common Stockholders
158.14M	168.10M	285.26M	272.05M	140.41M	229.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
145.31M	152.86M	204.31M	247.03M	231.55M	270.89M
	Total Assets
2.72B	2.70B	2.64B	2.29B	2.26B	2.03B
	Total Debt
494.73M	419.54M	454.96M	325.97M	420.55M	433.53M
	Net Debt
354.81M	267.75M	274.39M	153.40M	221.46M	286.90M
	Total Liabilities
706.79M	635.02M	672.18M	593.79M	691.72M	646.40M
	Stockholders Equity
2.01B	2.07B	1.97B	1.70B	1.57B	1.38B
Cash Flow		Free Cash Flow
254.30M	236.10M	216.15M	280.36M	307.86M	153.47M
	Operating Cash Flow
304.72M	298.98M	254.39M	325.27M	352.16M	205.22M
	Investing Cash Flow
-51.97M	-203.03M	-265.65M	-96.85M	-243.52M	27.09M
	Financing Cash Flow
-207.92M	-122.40M	22.62M	-242.85M	-62.55M	-183.80M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 49.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 49.28 is below the 20-day moving average (MA) of 49.80, below the 50-day MA of 53.77, and below the 200-day MA of 67.91, indicating a bearish trend. The MACD of -1.16 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 30.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	76 Outperform	$11.39B	22.04	9.64%	―	17.99%	152.10%
TECH	72 Outperform	$7.73B	59.91	6.53%	0.65%	4.72%	-35.33%
KRYS	72 Outperform	$3.82B	31.86	13.90%	―	247.53%	118.34%
INCY	71 Outperform	$12.35B	197.43	0.47%	―	17.13%	-88.78%
NAMS	54 Neutral	$2.14B	―	-31.51%	―	―	―
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
MRNA	43 Neutral	$10.21B	―	-29.34%	―	-38.25%	44.29%

Bio-Techne Corporate Events

Bio-Techne Reports Q3 2025 Financial Results

On May 7, 2025, Bio-Techne Corporation announced its financial results for the third quarter of fiscal 2025, reporting a 6% increase in organic revenue to $316.2 million. The company saw a decline in GAAP earnings per share to $0.14 from $0.31 a year ago, but adjusted EPS rose to $0.56. The Protein Sciences segment experienced 7% organic growth, driven by improved pharma market conditions and strong commercial execution. The adjusted operating margin increased to 34.9%, reflecting profitability initiatives and volume leverage. Despite a challenging macroenvironment, Bio-Techne’s strategic positioning and leadership are expected to help navigate current conditions, enhancing its financial performance and market presence.

Spark’s Take on TECH Stock

According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.

Bio-Techne’s strength lies in its robust financial performance and positive earnings call guidance. However, technical indicators suggest bearish momentum, and valuation concerns persist. A legal dispute poses a financial risk, though strategic board changes and revenue growth offer some optimism.

To see Spark’s full report on TECH stock, click here.

Bio-Techne Announces New $500M Share Repurchase Program

On April 30, 2025, Bio-Techne Corporation’s Board of Directors authorized a new share repurchase program, allowing the company to buy back up to $500 million of its common stock. This program replaces the previous one from February 2022 and has no set time limit. The repurchases can be made through various methods, including open market and private transactions, and are subject to market conditions and the company’s financial performance. The initiative aims to manage stock dilution and optimize capital needs, with disclosures to be made in the company’s annual and quarterly reports.

Spark’s Take on TECH Stock

According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.

Bio-Techne’s strength lies in its robust financial performance and positive earnings call guidance. However, technical indicators suggest bearish momentum, and valuation concerns persist. A legal dispute poses a financial risk, though strategic board changes and revenue growth offer some optimism.

To see Spark’s full report on TECH stock, click here.

Bio-Techne Ordered to Pay $35M in Stock Option Dispute

Bio-Techne Corporation faced a legal dispute regarding the expiration dates of stock options granted to its former CEO, Charles R. Kummeth. An administrative error led to a discrepancy in the expiration date of these options, resulting in arbitration. On February 26, 2025, an arbitrator ruled in favor of Mr. Kummeth, ordering the company to pay him approximately $35,978,000 for the options, along with interest and legal fees, due to the administrative error.